We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips reported stable quarterly earnings despite a slight revenue decline year over year.
Growth across all business segments boosted comparable sales and reflected solid market demand.
Cost-saving measures and productivity efforts strengthened margins and future growth guidance.
Koninklijke Philips (PHG - Free Report) reported earnings of €0.19 per share, which remained flat year over year.
The company’s sales decreased 1.7% on a year-over-year basis to €4.3 billion. Comparable sales increased 3% year over year, which was driven by growth across all segments. The Diagnosis & Treatment segment recorded 1% growth, Connected Care recorded 5% growth, and Personal Health showed 11% growth.
Further, Philips’ comparable order intake increased 8% year over year in the reported quarter.
Sales increased 3% year over year on a comparable basis in growth geographies. Growth geographies showed 5% growth, mainly driven by Personal Health. Comparable sales in Mature geographies grew 3% in the reported quarter, mainly driven by North America and with contributions from all segments.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Philips’ stock gained 2.06% in pre-market trading. The uptick can be attributed to growth across all segments.
PHG’s Segmental Update
Diagnosis & Treatment revenues declined 3.3% from the year-ago quarter to €2.08 billion. Comparable sales increased 1%. Image Guided Therapy showed low-single-digit growth, while Precision Diagnosis was flat.
Connected Care revenues decreased 0.9% year over year to €1.20 billion. Comparable sales increased 5% year over year, mainly due to double-digit growth in Monitoring.
Personal Health revenues grew 5.7% year over year to €883 million. Comparable sales increased 11%, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies.
Other segment sales amounted to €140 million, down 22.7% on a year-over-year basis.
PHG’s Operating Details
Gross margin contracted 140 basis points (bps) on a year-over-year basis to 44.4% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 3.6%, which expanded 10 bps on a year-over-year basis. Moreover, selling expenses decreased 80 bps year over year to 23.8%. Research & development expenses decreased 30 bps to 9.6%.
Restructuring, acquisition-related, and other items amounted to a loss of €122 million against a gain of €113 million a year ago.
Philips achieved €222 million in savings this quarter through disciplined cost management and robust productivity initiatives. The company remains on track to deliver its three-year €2.5 billion productivity program, including €800 million in savings in 2025.
Phillips adjusted EBITA — the company’s preferred measure of operational performance — increased 2.9% year over year to €531 million. EBITA margin expanded 50 bps on a year-over-year basis to 12.3% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin contracted 80 bps on a year-over-year basis to 11.8%.
Connected Care’s adjusted EBITA margin was 11.4% in the reported quarter, which expanded 410 bps year over year.
Personal Health’s adjusted EBITA margin expanded 60 bps on a year-over-year basis to 17.1%.
PHG’s Balance Sheet
As of Sept. 30, 2025, Philips’ cash and cash equivalents were €1.91 billion compared with €1.82 billion as of June 30, 2025.
Total debt was €8.385 billion compared with €8.425 billion as of June 30, 2025.
Operating cash flow was €327 million compared with the year-ago quarter’s €192 million.
In the quarter under review, free cash flow was €172 million compared with the year-ago quarter’s €22 million.
PHG Initiates 2025 Guidance
Philips expects to deliver 1-3% of comparable sales growth.
Further, the adjusted EBITA margin is expected to be between 11.3% and 11.8%
Free cash flow is expected to be between €0.2 billion and €0.4 billion in 2025, including the payout in the first quarter of 2025 of EUR 1,025 million for Philips Respironics recall-related medical monitoring and personal injury settlements in the United States.
Image: Bigstock
PHG Shares Rise Despite Posting Flat Y/Y Earnings & Revenue Dip in Q3
Key Takeaways
Koninklijke Philips (PHG - Free Report) reported earnings of €0.19 per share, which remained flat year over year.
The company’s sales decreased 1.7% on a year-over-year basis to €4.3 billion. Comparable sales increased 3% year over year, which was driven by growth across all segments. The Diagnosis & Treatment segment recorded 1% growth, Connected Care recorded 5% growth, and Personal Health showed 11% growth.
Further, Philips’ comparable order intake increased 8% year over year in the reported quarter.
Sales increased 3% year over year on a comparable basis in growth geographies. Growth geographies showed 5% growth, mainly driven by Personal Health. Comparable sales in Mature geographies grew 3% in the reported quarter, mainly driven by North America and with contributions from all segments.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
Philips’ stock gained 2.06% in pre-market trading. The uptick can be attributed to growth across all segments.
PHG’s Segmental Update
Diagnosis & Treatment revenues declined 3.3% from the year-ago quarter to €2.08 billion. Comparable sales increased 1%. Image Guided Therapy showed low-single-digit growth, while Precision Diagnosis was flat.
Connected Care revenues decreased 0.9% year over year to €1.20 billion. Comparable sales increased 5% year over year, mainly due to double-digit growth in Monitoring.
Personal Health revenues grew 5.7% year over year to €883 million. Comparable sales increased 11%, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies.
Other segment sales amounted to €140 million, down 22.7% on a year-over-year basis.
PHG’s Operating Details
Gross margin contracted 140 basis points (bps) on a year-over-year basis to 44.4% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 3.6%, which expanded 10 bps on a year-over-year basis. Moreover, selling expenses decreased 80 bps year over year to 23.8%. Research & development expenses decreased 30 bps to 9.6%.
Restructuring, acquisition-related, and other items amounted to a loss of €122 million against a gain of €113 million a year ago.
Philips achieved €222 million in savings this quarter through disciplined cost management and robust productivity initiatives. The company remains on track to deliver its three-year €2.5 billion productivity program, including €800 million in savings in 2025.
Phillips adjusted EBITA — the company’s preferred measure of operational performance — increased 2.9% year over year to €531 million. EBITA margin expanded 50 bps on a year-over-year basis to 12.3% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin contracted 80 bps on a year-over-year basis to 11.8%.
Connected Care’s adjusted EBITA margin was 11.4% in the reported quarter, which expanded 410 bps year over year.
Personal Health’s adjusted EBITA margin expanded 60 bps on a year-over-year basis to 17.1%.
PHG’s Balance Sheet
As of Sept. 30, 2025, Philips’ cash and cash equivalents were €1.91 billion compared with €1.82 billion as of June 30, 2025.
Total debt was €8.385 billion compared with €8.425 billion as of June 30, 2025.
Operating cash flow was €327 million compared with the year-ago quarter’s €192 million.
In the quarter under review, free cash flow was €172 million compared with the year-ago quarter’s €22 million.
PHG Initiates 2025 Guidance
Philips expects to deliver 1-3% of comparable sales growth.
Further, the adjusted EBITA margin is expected to be between 11.3% and 11.8%
Free cash flow is expected to be between €0.2 billion and €0.4 billion in 2025, including the payout in the first quarter of 2025 of EUR 1,025 million for Philips Respironics recall-related medical monitoring and personal injury settlements in the United States.
PHG’s Zacks Rank & Other Stocks to Consider
Philips currently has a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader Zacks Medical sector are Akamai Technologies (AKAM - Free Report) , KE Holdings (BEKE - Free Report) , and Analog Devices (ADI - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Akamai Technologies is set to report third-quarter 2025 results on Nov. 06. AKAM shares have plunged 23.3% year to date.
KE Holdings is slated to report third-quarter 2025 results on Nov. 10. BEKE shares have plunged 11.2% year to date.
Analog Devices is set to report fiscal fourth-quarter 2025 results on Nov. 25. ADI shares have gained 8.4% year to date.